{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:53Z","timestamp":1777383173048,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11739-010-0369-6","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T13:00:23Z","timestamp":1268658023000},"page":"375-384","source":"Crossref","is-referenced-by-count":26,"title":["Polycythemia vera"],"prefix":"10.1007","volume":"5","author":[{"given":"Raffaele","family":"Landolfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Anna","family":"Nicolazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Porfidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,16]]},"reference":[{"key":"369_CR1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097","journal-title":"Blood"},{"key":"369_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14\u201322","journal-title":"Leukemia"},{"key":"369_CR3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/157488809788167445","volume":"4","author":"E Spanoudakis","year":"2009","unstructured":"Spanoudakis E, Tsatalas C (2009) Hemopoiesis in Ph-negative chronic myeloproliferative disorders. Curr Stem Cell Res Ther 4:154\u2013160","journal-title":"Curr Stem Cell Res Ther"},{"key":"369_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 59:171\u2013191","journal-title":"CA Cancer J Clin"},{"key":"369_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","volume":"41","author":"JL Spivak","year":"2004","unstructured":"Spivak JL (2004) The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 41:1\u20135","journal-title":"Semin Hematol"},{"key":"369_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11739-009-0284-x","volume":"4","author":"F Fabris","year":"2009","unstructured":"Fabris F, Randi ML (2009) Essential thrombocythemia: past and present. Intern Emerg Med 4:381\u2013388","journal-title":"Intern Emerg Med"},{"key":"369_CR7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research, Treatment (IWG-MRT) (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437\u2013438","journal-title":"Leukemia"},{"key":"369_CR8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/leu.2009.54","volume":"23","author":"MM Patnaik","year":"2009","unstructured":"Patnaik MM, Tefferi A (2009) The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 23:834\u2013844","journal-title":"Leukemia"},{"key":"369_CR9","first-page":"60","volume":"12","author":"H Vaquez","year":"1895","unstructured":"Vaquez H (1895) Sur une forme speciale de cyanose s\u2019accompanant d\u2019hyperglobulie excessive et peristente (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis). Compt rend Soc de biol and suppl note. Bull et mem Soc med d\u2019hop de Paris 12:60","journal-title":"Bull et mem Soc med d\u2019hop de Paris"},{"key":"369_CR10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJM190006141422401","volume":"142","author":"RC Cabot","year":"1900","unstructured":"Cabot RC (1900) A second case of chronic cyanosis without assignable cause. Boston Med Surg J 142:275","journal-title":"Boston Med Surg J"},{"key":"369_CR11","first-page":"143","volume":"1","author":"W Osler","year":"1908","unstructured":"Osler W (1908) A clinical lecture on erythraemia (polycythaemia with cyanosis, maladie de Vaquez). Lancet 1:143\u2013146","journal-title":"Lancet"},{"key":"369_CR12","first-page":"183","volume":"23","author":"LR Wasserman","year":"1986","unstructured":"Wasserman LR (1986) Polycythemia Vera Study Group: a historical perspective. Semin Hematol 23:183\u2013187","journal-title":"Semin Hematol"},{"key":"369_CR13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"369_CR14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"369_CR15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Project Cancer Genome (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"369_CR16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"369_CR17","doi-asserted-by":"crossref","unstructured":"Vannucchi AM (2009) Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med [Epub ahead of print]","DOI":"10.1007\/s11739-009-0319-3"},{"key":"369_CR18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI108706","volume":"59","author":"ED Zanjani","year":"1977","unstructured":"Zanjani ED, Lutton JD, Hoffman R, Wasserman LR (1977) Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest 59:841","journal-title":"J Clin Invest"},{"key":"369_CR19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.seminhematol.2005.08.002","volume":"42","author":"R Skoda","year":"2005","unstructured":"Skoda R, Prchal JT (2005) Lessons from familial myeloproliferative disorders. Semin Hematol 42:266\u2013273","journal-title":"Semin Hematol"},{"key":"369_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459\u2013468","journal-title":"N Engl J Med"},{"key":"369_CR21","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472\u20133476","journal-title":"Blood"},{"key":"369_CR22","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della Valle V et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289\u20132301","journal-title":"N Engl J Med"},{"key":"369_CR23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004: utilizing data from the NAACCR and SEER programs. Blood 112:45\u201352","journal-title":"Blood"},{"key":"369_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia 22:905\u2013914","journal-title":"Leukemia"},{"key":"369_CR25","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232","journal-title":"J Clin Oncol"},{"key":"369_CR26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124","journal-title":"N Engl J Med"},{"key":"369_CR27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0889-8588(03)00090-X","volume":"17","author":"JT Prchal","year":"2003","unstructured":"Prchal JT (2003) Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 17:1151","journal-title":"Hematol Oncol Clin North Am"},{"key":"369_CR28","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3324\/haematol.2009.007047","volume":"94","author":"L Pieri","year":"2009","unstructured":"Pieri L, Bogani C, Guglielmelli P et al (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94:1537\u20131545","journal-title":"Haematologica"},{"key":"369_CR29","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","volume":"113","author":"T Ishii","year":"2009","unstructured":"Ishii T, Wang J, Zhang W et al (2009) Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113:5942\u20135950","journal-title":"Blood"},{"key":"369_CR30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.2002.03380.x","volume":"117","author":"G Torgano","year":"2002","unstructured":"Torgano G, Mandelli C, Massaro P, Abbiati C (2002) Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori. Br J Haematol 117:198","journal-title":"Br J Haematol"},{"key":"369_CR31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2006-939431","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, Berneman Z, Bockstaele DV et al (2006) Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 32:174\u2013207","journal-title":"Semin Thromb Hemost"},{"key":"369_CR32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","unstructured":"Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20\u00a0years. Ann Intern Med 123:656\u2013664","journal-title":"Ann Intern Med"},{"key":"369_CR33","first-page":"1011","volume":"85","author":"F Passamonti","year":"2000","unstructured":"Passamonti F, Brusamolino E, Lazzarino M et al (2000) Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 85:1011\u20131018","journal-title":"Haematologica"},{"key":"369_CR34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138:354\u2013358","journal-title":"Br J Haematol"},{"key":"369_CR35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","volume":"5","author":"V Stefano De","year":"2007","unstructured":"De Stefano V, Fiorini A, Rossi E et al (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5:708\u2013714","journal-title":"J Thromb Haemost"},{"key":"369_CR36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-2006-939432","volume":"32","author":"JB Briere","year":"2006","unstructured":"Briere JB (2006) Budd\u2013Chiari Syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Haemost Thrombosis 32:208\u2013218","journal-title":"Semin Haemost Thrombosis"},{"key":"369_CR37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1538-7836.2007.02811.x","volume":"6","author":"V Ugo","year":"2008","unstructured":"Ugo V, Le Gal G, Lecucq L, Mottier D, Oger E, Collaborative Study Group EDITH (2008) Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost 6:203\u2013205","journal-title":"J Thromb Haemost"},{"key":"369_CR38","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) Leukocytosis as a major thrombotic risk factor in patients with Polycythemia Vera. Blood 109:2446\u20132452","journal-title":"Blood"},{"key":"369_CR39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2008.177","volume":"22","author":"T Barbui","year":"2008","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G (2008) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Leukemia 22:1494\u20131502","journal-title":"Leukemia"},{"key":"369_CR40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mic\u00f2 C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T, GIMEMA Chronic Myeloproliferative Neoplasms Working Party (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85:97\u2013100","journal-title":"Am J Hematol"},{"key":"369_CR41","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","volume":"22","author":"R Landolfi","year":"2008","unstructured":"Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22:2020\u20132028","journal-title":"Leukemia"},{"key":"369_CR42","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","volume":"80","author":"R Landolfi","year":"1992","unstructured":"Landolfi R, Ciabattoni G, Patrignani P et al (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965","journal-title":"Blood"},{"key":"369_CR43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","volume":"37","author":"A Carobbio","year":"2009","unstructured":"Carobbio A, Finazzi G, Antonioli E et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37:1016\u20131021","journal-title":"Exp Hematol"},{"key":"369_CR44","first-page":"172","volume":"23","author":"A Tartaglia","year":"1986","unstructured":"Tartaglia A, Goldberg J, Berk P, Wasserman L (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172\u2013176","journal-title":"Semin Hematol"},{"key":"369_CR45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","volume":"19","author":"R Landolfi","year":"2006","unstructured":"Landolfi R, Cipriani MC, Novarese L (2006) Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 19:617\u2013633","journal-title":"Best Pract Res Clin Haematol"},{"key":"369_CR46","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373\u20132383","journal-title":"N Engl J Med"},{"key":"369_CR47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","volume":"146","author":"A Alvarez-Larr\u00e1n","year":"2009","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Mart\u00ednez-Avil\u00e9s L et al (2009) Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 146:504\u2013509","journal-title":"Br J Haematol"},{"key":"369_CR48","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, ECLAP Investigators (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664\u20132670","journal-title":"Blood"},{"key":"369_CR49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11739-007-0003-4","volume":"2","author":"G Finazzi","year":"2007","unstructured":"Finazzi G, Barbui T (2007) The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med 2:13\u201318","journal-title":"Intern Emerg Med"},{"key":"369_CR50","first-page":"166","volume-title":"Polycythemia vera and the myeloproliferative disorders","author":"PD Berk","year":"1995","unstructured":"Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. WB Saunders, Philadelphia, p 166"},{"key":"369_CR51","first-page":"6","volume":"34","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain J-D (1997) The very long term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 34:6\u201316","journal-title":"Semin Hematol"},{"key":"369_CR52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2141.1995.tb08941.x","volume":"89","author":"M Messinezy","year":"1995","unstructured":"Messinezy M, Pearson TC (1995) Incidence of myelofibrosis following treatment of primary polycythaemia by venesection. Br J Haematol 89:228\u2013230","journal-title":"Br J Haematol"},{"key":"369_CR53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","volume":"2","author":"RT Silver","year":"1988","unstructured":"Silver RT (1988) Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2:403","journal-title":"Lancet"},{"key":"369_CR54","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22:1990","journal-title":"Leukemia"},{"key":"369_CR55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","volume":"92","author":"Anagrelide Study Group","year":"1992","unstructured":"Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69\u201376","journal-title":"Am J Med"},{"key":"369_CR56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2141.1997.362682.x","volume":"97","author":"Gruppo Italiano Studio Policitemia","year":"1997","unstructured":"Gruppo Italiano Studio Policitemia (1997) Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol 97:453\u2013456","journal-title":"Br J Haematol"},{"key":"369_CR57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MOH.0b013e3283257a9e","volume":"16","author":"G Barosi","year":"2009","unstructured":"Barosi G, Rosti V (2009) Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol 16:129\u2013134","journal-title":"Curr Opin Hematol"},{"key":"369_CR58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.exphem.2007.03.012","volume":"35","author":"A Gaikwad","year":"2007","unstructured":"Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT (2007) Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol 35:931\u2013938","journal-title":"Exp Hematol"},{"key":"369_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/138945007779940124","volume":"8","author":"A Reiter","year":"2007","unstructured":"Reiter A, Walz C, Cross NC (2007) Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 8:205\u2013216","journal-title":"Curr Drug Targets"},{"key":"369_CR60","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673\u2013683","journal-title":"Nat Rev Cancer"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-010-0369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-010-0369-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-010-0369-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T03:16:54Z","timestamp":1711336614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-010-0369-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,16]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1007\/s11739-010-0369-6","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,16]]}}}